Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

6.47
+0.27004.35%
Post-market: 6.470.00000.00%19:54 EST
Volume:1.04M
Turnover:7.10M
Market Cap:417.14M
PE:-10.96
High:7.13
Open:6.57
Low:6.46
Close:6.20
52wk High:7.13
52wk Low:0.7260
Shares:64.47M
Float Shares:44.93M
Volume Ratio:1.41
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5905
EPS(LYR):-0.7575
ROE:-3727.94%
ROA:-87.09%
PB:-3.32
PE(LYR):-8.54

Loading ...

Company Profile

Company Name:
Galectin Therapeutics
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
15
Office Location:
4960 Peachtree Industrial Boulevard,Suite 240,Norcross,Georgia,United States
Zip Code:
30071
Fax:
- -
Introduction:
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Directors

Name
Position
Joel Lewis
Director,Chief Executive Officer and President
Richard E. Uihlein
Chairman
Elissa J. Schwartz
Independent Director
Gilbert F. Amelio
Independent Director
Gilbert S. Omenn
Independent Director
Harold H. Shlevin
Independent Director,Chief Operating Officer and Secretary
Kary Eldred
Independent Director
Kevin D. Freeman
Independent Director
Marc Rubin
Independent Director
Richard A. Zordani
Independent Director
Benjamin S. Carson, Sr.
Director

Shareholders

Name
Position
Joel Lewis
Director,Chief Executive Officer and President
Harold H. Shlevin
Independent Director,Chief Operating Officer and Secretary
Jack W. Callicutt
Chief Financial Officer
Khurram Jamil
Chief Medical Officer